To Present pre|CISION® Dual Payload Candidate
In brief · summary, not quotable
Avacta to present AVA6207 dual payload PDC candidate at EORTC-NCI-AACR Symposium in Barcelona.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
| Avacta to Present the pre | CISION® Dual Payload Candidate AVA6207 at the 2026 EORTC-NCI-AACR Symposium | |
| LONDON and PHILADELPHIA – November 4, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces it will present AVA6207, its Next-Generation pre | CISION® dual payload peptide-drug conjugate (PDC), in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from November 18-20. | |
| AVA6207 uses the Company’s pre | CISION® PDC technology to deliver two synergistic payloads directly to tumor cells in a single molecule, combining two complementary mechanisms to combat highly resistant cancers. This dual payload molecule functions by inhibiting topoisomerase I (TOP1), inducing severe DNA damage, while simultaneously inhibiting Ataxia Telangiectasia and Rad3-related (ATR) kinase through an ATR inhibitor (ATRi), thus blocking the DNA damage response to prevent cancer cells from repairing TOP1 inhibitor (TOP1i)-induced damage. Combining these two payloads into one pre | CISION® PDC that delivers them directly to the tumor has tremendous potential to improve outcomes in TOP1i-resistant cancers, a growing area of unmet need in oncology. |
| Details of the poster presentation | ||
| Title: AVA6207 is a novel pre | CISION® technology compound delivering complementary TOP1i and ATRi payloads to the tumor microenvironment following FAP cleavage | |
Authors: Victoria Juskaite, Tom Clough, Ellen Watts, et al. and David Jones
Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)
Session Date and Time: Thursday, November 19, 09:00-17:30
Location: Exhibition Hall, Poster Area
Abstract Number: 161
| Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre | CISION® platform. pre | CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre | CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. |
| Our pre | CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre | CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer. |
About FAP-Exd (AVA6103)
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.